A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

Merck (NYSE:MRK) shares inched higher on Friday after Summit Therapeutics (NASDAQ:SMMT) announced the latest survival data ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

Drugmaker Merck reports quarterly results Thursday morning as fears grow over the expiration of the patent on its top-selling ...

California-based biotech Halozyme Therapeutics (Nasdaq: HALO) yesterday revealed it has filed a patent infringement lawsuit ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Halozyme (HALO) filed a patent infringement lawsuit against Merck (MRK) in U.S. District Court in New Jersey. Halozyme believes the ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase ...